SunTrust Banks Reiterates Buy Rating for Edwards Lifesciences (EW)

SunTrust Banks restated their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a report released on Tuesday morning. They currently have a $180.00 price objective on the medical research company’s stock. SunTrust Banks also issued estimates for Edwards Lifesciences’ Q1 2018 earnings at $1.12 EPS, Q2 2018 earnings at $1.16 EPS, Q3 2018 earnings at $1.05 EPS, Q4 2018 earnings at $1.21 EPS, FY2018 earnings at $4.55 EPS, Q1 2019 earnings at $1.30 EPS, Q2 2019 earnings at $1.34 EPS, Q3 2019 earnings at $1.22 EPS, Q4 2019 earnings at $1.40 EPS and FY2019 earnings at $5.25 EPS.

Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Edwards Lifesciences from a hold rating to a buy rating and set a $145.00 price objective for the company in a research report on Thursday, February 8th. Guggenheim reissued a buy rating and set a $162.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. JMP Securities boosted their target price on Edwards Lifesciences from $135.00 to $140.00 and gave the stock a market outperform rating in a report on Friday, February 2nd. Cowen reissued a buy rating and set a $150.00 target price on shares of Edwards Lifesciences in a report on Thursday, February 1st. Finally, Stifel Nicolaus reissued a buy rating and set a $155.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $145.92.

Shares of NYSE EW opened at $137.84 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41. The company has a market cap of $29,252.10, a PE ratio of 36.27, a price-to-earnings-growth ratio of 2.04 and a beta of 0.58. Edwards Lifesciences has a 12-month low of $93.67 and a 12-month high of $143.22.



Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The business’s revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 earnings per share. analysts predict that Edwards Lifesciences will post 4.53 earnings per share for the current year.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $127.24, for a total value of $674,372.00. Following the transaction, the vice president now owns 24,908 shares of the company’s stock, valued at $3,169,293.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jean-Luc M. Lemercier sold 5,633 shares of the company’s stock in a transaction on Wednesday, April 11th. The shares were sold at an average price of $139.42, for a total value of $785,352.86. The disclosure for this sale can be found here. Insiders sold 197,236 shares of company stock worth $26,375,070 in the last ninety days. 1.84% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in EW. Cerebellum GP LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $128,000. Resources Investment Advisors Inc. raised its stake in Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the period. Exane Derivatives raised its stake in Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the period. Lake Street Advisors Group LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $201,000. Finally, Captrust Financial Advisors acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $204,000. 82.96% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://dakotafinancialnews.com/2018/04/14/suntrust-banks-reiterates-buy-rating-for-edwards-lifesciences-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply